NKTR

Nektar Therapeutics

A biopharmaceutical company that uses a technology called PEGylation—attaching polymer chains to drugs so they dissolve better and last longer in the body—and now focuses on therapies for immune and inflammatory diseases. It began in 1990 as Inhale Therapeutic Systems, a firm known for inhaled drug delivery, and took the name Nektar in 2003 to signal a broader mission. The name plays on "nectar," a sweet nod for a company whose famous early product was the inhaled insulin Exubera.

CUSIP: 640268108HealthcareUS1 holder

Ownership Activity Financials Filings

NKTR

NKTR

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Regulation FD Disclosure

Results of Operations and Financial Condition